FI104374B - T-cellepitop-oligopeptider och framställning av konjugat som innehåller dessa - Google Patents
T-cellepitop-oligopeptider och framställning av konjugat som innehåller dessa Download PDFInfo
- Publication number
- FI104374B FI104374B FI903292A FI903292A FI104374B FI 104374 B FI104374 B FI 104374B FI 903292 A FI903292 A FI 903292A FI 903292 A FI903292 A FI 903292A FI 104374 B FI104374 B FI 104374B
- Authority
- FI
- Finland
- Prior art keywords
- crm
- peptide
- cell
- prp
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Optical Couplings Of Light Guides (AREA)
Claims (16)
1. Oligopeptid, kännetecknad av, att den väsentligen bestär av ätminstone en T-cellepitop frän 5 ett bakteriellt toxin, CRM eller en toxoid.
2. Oligopeptid enligt patentkrav 1, kännetecknad av, att den väsentligen bestär av en T-cellepitop frän CRMi97 med aminosyrasekvensen hos CRMi97-peptiden 357 - 383, CRMi97-peptiden 366 - 383, CRM197-pepti- 10 den 369 - 383, CRMi97-peptiden 306 - 334 eller antigena va-' rianter därav, som inte stör aktiviteten hos epitopen.
3. Oligopeptid enligt patentkrav 1, kännetecknad av, att den väsentligen bestär av en T-cellepitop frän tetanustoxin eller -toxoid med aminosyra- 15 sekvensen hos tetanustoxid-peptiden 961 - 980, tatanustox-id-peptiden 1021 - 1040 eller antigena varianter därav, som inte stör aktiviteten hos epitopen.
4. Oligopeptid enligt patentkrav 1, kännetecknad av, att den väsentligen bestär av en T- 20 cellepitop frän ett bakteriellt toxin, CRM eller en toxoid : med aminosyrasekvensen QWHNSYNRPAYSPG, NLFQWHNSYNRPAYSPG, AYNFVE (ellerG) SIINLFQWHNSYNRPAYSPG, ILPGIGSVMGIADGAVHHNTEEIVAQSIA, VSASHLEQYGTNEYSIISSM eller DKFNAYLANKWVFITITNDR. • · 25
5. Oligopeptid enligt patentkrav 4, k ä n n e - t e c k n a d av, att en lysin- eller cysteingrupp kopp- M· V * lats tili amino- eller karboxiterminalen eller bäda.
6. Oligopeptid enligt patentkrav 5, k ä n n e - t e c k n a d av, att en lysin- eller cysteingrupp kopp- ;*·*: 30 lats tili amino- eller karboxiterminalen medelst en glycin- • . rest.
7. Förfarande för framställning av ett immunogent konjugat, kännetecknat av, att man kopplar en polysackaridantigen tili en oligopeptid, som väsentligen , 35 bestär av ätminstone en T-cellepitop frän ett bakteriellt toxin, CRM eller en toxoid. 104374
8. Förfarande enligt patentkrav 7, känne-t e c k n a t av, att det bakteriella toxinet, CRM:t eller toxoiden är difteriatoxin, tetanustoxin, pertussistoxin, CRM197, toxoid eller tetanustoxoid. 5
9. Förfarande enligt patentkrav 8, känne- t e c k n a t av, att epitopen har aminosyrasekvensen hos CRMi97-peptiden 357 - 383, CRM197-peptiden 366 - 383, CRM197-peptiden 369 - 383, CRMi97~peptiden 306 - 334, tetaustoxin-peptiden 961 - 980, tetanustoxin-peptiden 1021 - 1040 eller 10 antigena varianter därav, som inte stör aktiviteten hos epitopen.
10. Förfarande enligt patentkrav 7, känne- t e c k n a t av, att antigenen härstammar frän en mik-rob-, virus-, eller parasitantigen, tumörantigen, allergen 15 eller en antigen som hör ihop med autoimmunitet.
11. Förfarande enligt patentkrav 10, känne- t e c k n a t av, att antigenen är en kapselpolymer, eller en oligomer eller ett fragment därav.
12. Förfarande enligt patentkrav 11, känne- 20 tecknat av, att kapselpolymeren eller -oligomeren härstammar frän Haemophilus influenzae-, Streptococcus pneumoniae-, Neisseria meningitidis- eller Salmonella typhi -bakterier.
13. Förfarande enligt patentkrav 12, känne- .. 25 tecknat av, att kapselpolymeren är polyribosylribi- • · · Σ...5 tolfosfat frän H. influenzae. Γ:
! 14. Förfarande enligt patentkrav 12, k ä n n e - tecknat av, att kapselpolymeren härstammar frän se-rotyp 1, 4, 5, 6A, 6B, 9V, 14, 18C, 19F eller 23F av Strep-30 tococcus pneumoniae. m
· · *· 15. Förfarande enligt patentkrav 7, känne- **· tecknat av, att antigenen kopplas till en oligomer " med aminosyrasekvensen QWHNSYNRPAYSPG, NLFQWHNSYNRPAYSPG, : AYNFVE (ellerG) SIINLFQWHNSYNRPAYSPG, ILPGIGSVMGI-
35 ADGAVHHNTEEIVAQSIA, VSASHLEQYGTNEYSIISSM eller DKFNAY- LANKWVFITITNDR. « I 76 1 0 4 3 7 4
16. Förfarande enligt patentkrav 7, kanne-t e c k n a t av, att antigenen härstainmar frän en bakte-riell ytsackarid eller en bakteriell cellväggssackarid. I I * ( I I I • · • · · • · • 9 • · · • · t • I · • · · • · 1 I I · • · · • M I « I « I l « * • · I ( l I I I (
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15068888A | 1988-02-01 | 1988-02-01 | |
US15068888 | 1988-02-01 | ||
US8900388 | 1989-01-31 | ||
PCT/US1989/000388 WO1989006974A2 (en) | 1988-02-01 | 1989-01-31 | T-cell epitope as carriers molecule for conjugate vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
FI903292A0 FI903292A0 (fi) | 1990-06-29 |
FI104374B true FI104374B (sv) | 2000-01-14 |
Family
ID=22535596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI903292A FI104374B (sv) | 1988-02-01 | 1990-06-29 | T-cellepitop-oligopeptider och framställning av konjugat som innehåller dessa |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0399001B1 (sv) |
JP (1) | JP2921574B2 (sv) |
AT (1) | ATE109008T1 (sv) |
AU (1) | AU634153B2 (sv) |
CA (2) | CA1340956C (sv) |
DE (1) | DE68917126T2 (sv) |
DK (1) | DK174416B1 (sv) |
FI (1) | FI104374B (sv) |
NO (1) | NO179164C (sv) |
WO (1) | WO1989006974A2 (sv) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2546544B2 (ja) * | 1989-10-27 | 1996-10-23 | アーチ ディベラップメント コーポレイション | 免疫強化を促進するための方法と組成物 |
GB8924438D0 (en) * | 1989-10-31 | 1989-12-20 | Hoffmann La Roche | Vaccine composition |
US5500366A (en) * | 1990-09-18 | 1996-03-19 | Biotech Australia Pty. Ltd. | Polynucleotide encoding T-cell epitopes of the protein TraT |
WO1993011157A1 (en) * | 1991-11-27 | 1993-06-10 | The Council Of The Queensland Institute Of Medical Research | MALARIAL VACCINE AND PEPTIDES COMPRISING HUMAN T-CELL EPITOPE OF CIRCUMSPOROZOITE PROTEIN OF $i(P.VIVAX) |
IL105503A (en) * | 1992-04-28 | 1999-05-09 | Astra Ab | Carbon peptide couplets capable of eliciting an immune response of T cells |
AU4580093A (en) * | 1992-07-22 | 1994-02-14 | Proteus Molecular Design Limited | Polypeptide antigens of mycobacterium bovis |
CA2141427C (en) * | 1992-07-31 | 2008-07-22 | Mohammed Anjam Khan | Expression of recombinant fusion proteins in attenuated bacteria |
BR9306984A (pt) | 1992-08-27 | 1999-01-12 | Deakin Res Ltd | Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo |
DK140992D0 (da) * | 1992-11-24 | 1992-11-24 | Ole Buchardt | Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug |
US5759551A (en) * | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
GB9401787D0 (en) | 1994-01-31 | 1994-03-23 | Medeva Holdings Bv | Vaccine compositions |
EP0712442B1 (en) * | 1993-07-30 | 2002-03-27 | Medeva Holdings B.V. | Vaccine compositions |
GB9401795D0 (en) * | 1994-01-31 | 1994-03-23 | Medeva Holdings Bv | Vaccines |
GB2295394B (en) * | 1994-01-31 | 1997-09-24 | Medeva Holdings Bv | DNA encoding a fusion protein comprising the C fragment of tetanus toxin |
AU1864195A (en) * | 1994-03-07 | 1995-09-25 | Auckland Uniservices Limited | Prevention of diabetes |
DE69630877T2 (de) * | 1995-03-31 | 2004-11-11 | Xenova Research Ltd., Slough | Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie |
US5773003A (en) * | 1995-03-31 | 1998-06-30 | Immulogic, Inc. | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
US5843462A (en) * | 1995-11-30 | 1998-12-01 | Regents Of The University Of Minnesota | Diphtheria toxin epitopes |
US7709002B1 (en) | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
EP0895538B1 (en) | 1996-04-19 | 2002-07-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes |
GB9713156D0 (en) * | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
TWI229679B (en) | 1998-06-20 | 2005-03-21 | United Biomedical Inc | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens |
US6025468A (en) | 1998-06-20 | 2000-02-15 | United Biomedical, Inc. | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides |
DE19856052A1 (de) * | 1998-12-04 | 2000-06-08 | Deutsches Krebsforsch | Konjugat zur Anreicherung in neuronalen Zellen |
AU2002231621A1 (en) | 2000-11-09 | 2002-05-21 | Immunolex Laboratories | Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins |
KR20110084906A (ko) | 2008-10-10 | 2011-07-26 | 에라 바이오테크, 에스.에이. | 면역원-특이적 면역보강제로서의 재조합 단백질체들 |
US9358302B2 (en) * | 2009-03-23 | 2016-06-07 | The Brigham And Women's Hospital, Inc. | Glycoconjugate vaccines |
EP2418284A1 (en) | 2010-08-13 | 2012-02-15 | ERA Biotech, S.A. | Protein body-inducing polypeptide sequences |
EP2870974A1 (en) * | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
KR20190103256A (ko) | 2016-12-30 | 2019-09-04 | 수트로박스, 인코포레이티드 | 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체 |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
AU2019299836A1 (en) | 2018-07-04 | 2021-02-25 | Vaxcyte, Inc. | Improvements in immunogenic conjugates |
WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
WO2020010000A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US4808700A (en) * | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
NZ214503A (en) * | 1984-12-20 | 1990-02-26 | Merck & Co Inc | Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates |
-
1989
- 1989-01-31 DE DE68917126T patent/DE68917126T2/de not_active Expired - Fee Related
- 1989-01-31 WO PCT/US1989/000388 patent/WO1989006974A2/en active IP Right Grant
- 1989-01-31 JP JP1502396A patent/JP2921574B2/ja not_active Expired - Fee Related
- 1989-01-31 EP EP89908669A patent/EP0399001B1/en not_active Expired - Lifetime
- 1989-01-31 AT AT89908669T patent/ATE109008T1/de not_active IP Right Cessation
- 1989-01-31 AU AU30654/89A patent/AU634153B2/en not_active Ceased
- 1989-02-01 CA CA000589806A patent/CA1340956C/en not_active Expired - Fee Related
- 1989-02-01 CA CA000616882A patent/CA1340958C/en not_active Expired - Fee Related
-
1990
- 1990-06-29 NO NO902909A patent/NO179164C/no not_active IP Right Cessation
- 1990-06-29 FI FI903292A patent/FI104374B/sv not_active IP Right Cessation
- 1990-07-31 DK DK199001829A patent/DK174416B1/da not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU3065489A (en) | 1989-08-25 |
DK182990D0 (da) | 1990-07-31 |
CA1340958C (en) | 2000-04-11 |
NO179164C (no) | 1996-08-21 |
DE68917126D1 (de) | 1994-09-01 |
DE68917126T2 (de) | 1995-02-02 |
AU634153B2 (en) | 1993-02-18 |
CA1340956C (en) | 2000-04-11 |
DK174416B1 (da) | 2003-02-17 |
WO1989006974A2 (en) | 1989-08-10 |
NO902909D0 (no) | 1990-06-29 |
ATE109008T1 (de) | 1994-08-15 |
JPH03502691A (ja) | 1991-06-20 |
FI903292A0 (fi) | 1990-06-29 |
DK182990A (da) | 1990-07-31 |
EP0399001B1 (en) | 1994-07-27 |
NO902909L (no) | 1990-08-27 |
NO179164B (no) | 1996-05-13 |
WO1989006974A3 (en) | 1989-08-24 |
EP0399001A1 (en) | 1990-11-28 |
JP2921574B2 (ja) | 1999-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI104374B (sv) | T-cellepitop-oligopeptider och framställning av konjugat som innehåller dessa | |
US5785973A (en) | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines | |
AU634154B2 (en) | Decoupled fiber optic feedthrough assembly | |
Paoletti et al. | Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. | |
US5425946A (en) | Vaccines against group C Neisseria meningitidis | |
CA2142981C (en) | Vaccines against group c neisseria meningitidis | |
AU572821B2 (en) | Synthetic heat-stable enterotoxin polypeptide of escherichia coli and multimers thereof | |
US5773007A (en) | Vaccine compositions | |
EP0427347B1 (en) | Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines | |
AU754890B2 (en) | Enterococcus antigens and vaccines | |
KR101446238B1 (ko) | 단백질 매트릭스 백신 및 그의 제조방법 및 백신 투여방법 | |
Paoletti et al. | An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus. | |
PL174082B1 (pl) | Koniugat kapsularnego polisacharydu (Vi) i związanego z nim nośnika oraz sposób wytwarzania koniugatu | |
JPH11507964A (ja) | 2,5−アンヒドロ−d−マンノース末端構造を持つ、抗原性グループb連鎖球菌▲ii▼型および▲iii▼型多糖断片とその複合ワクチン | |
US5043158A (en) | Immunogenic compositions containing ordered carriers | |
BR112012009014B1 (pt) | Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica | |
Elsayed et al. | Synthetic allergenic epitopes from the amino-terminal regions of the major allergens of hazel and birch pollen | |
EP0302887A1 (en) | BACTERIAL ANTIGENS, ANTIBODIES, VACCINE AND THEIR PRODUCTION. | |
Richter et al. | Preparation of dextran-protein conjugates and studies of their immunogenicity | |
Lett et al. | Immunogenicity of polysaccharides conjugated to peptides containing T-and B-cell epitopes | |
Jennings | Further approaches for optimizing polysaccharide-protein conjugate vaccines for prevention of invasive bacterial disease | |
Lugowski et al. | Enterobacterial common antigen-tetanus toxoid conjugate as immunogen | |
WO1991012819A1 (en) | Improved immunogenic compositions | |
Michaelides | Chemical and enzymatic fragmentation of tetanus toxin and immunological studies on anti-tetanus toxin and toxoid sera. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Owner name: WYETH HOLDINGS CORPORATION |
|
MA | Patent expired |